- https://doi.org/10.2174/0118715257341062250130103015
Long-term Sustained Response to Lenalidomide after Clearance of Bone Marrow Blasts by Azacytidine in High-risk Myelodysplastic Syndromes with Del5q: A Case Report.
Translate Article 
Take Notes This report discusses a rare case involving a patient with high-risk (HR) Del(5q) myelodysplastic syndrome (MDS) who achieved a long-term response to lenalidomide after having received six cycles of azacytidine. The latter treatment led to the clearance of blast cells from the bone marrow (BM). As per current clinical practice, patients with HR MDS receive azacytidine continuously until the disease progresses or the occurrence of unmanageable side effects. However, in this case, the patient decided to interrupt hypomethylation therapy. Due to the patient's preference for oral therapy at home, the absence of blast cells, the ongoing need for transfusions, and a cytogenetic abnormality-predictive response to lenalidomide, the choice of the latter agent allowed for a sustained response lasting up to 68 months. Our observations suggest that further studies could explore the sequential use of azacytidine followed by lenalidomide after achieving BM blast clearance in patients with HR MDS with del(5q).
- Front Matter
21 - 10.1111/bjh.17612
- Jun 27, 2021
- British Journal of Haematology
British Society for Haematology guidelines for the management of adult myelodysplastic syndromes.
- Abstract
- 10.1182/blood.v116.21.612.612
- Nov 19, 2010
- Blood
Predisposition to Myelodysplastic Syndrome with Deletion 5q Is Associated with TP53 Codon 72 Genotype
- Front Matter
- 124
- 10.1016/j.annonc.2020.11.002
- Nov 19, 2020
- Annals of Oncology
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆
- Abstract
- 10.1182/blood.v120.21.2823.2823
- Nov 16, 2012
- Blood
Association of MDM2 Gene Polymorphisms SNP285 and 309 with Myelodysplastic Syndromes (MDS) Susceptibility and Outcome.
- News Article
- 10.4161/cbt.5.2.2506
- Feb 1, 2006
- Cancer Biology & Therapy
REVLIMID (lenalidomide) Approved by FDA for Transfusion-Dependent Anemia Associated with Myelodisplastic Syndrome
- Abstract
- 10.1182/blood.v118.21.5020.5020
- Nov 18, 2011
- Blood
POTENTIAL ROLE of 8-COLOR FLOW CYTOMETRY for CHARACTERIZATION of MDS with Del(5q) ABNORMALITIES
- Abstract
- 10.1182/blood-2019-125806
- Nov 13, 2019
- Blood
Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group
- Research Article
- 10
- 10.1200/jco.2011.35.2211
- Apr 25, 2011
- Journal of Clinical Oncology
Myelodysplastic Syndromes: Dissecting the Heterogeneity
- Front Matter
- 11
- 10.1111/bjh.17621
- Jun 16, 2021
- British Journal of Haematology
British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes.
- Abstract
- 10.1182/blood.v124.21.1898.1898
- Dec 6, 2014
- Blood
A Calcium-Dependent Pathway Determines Response to Lenalidomide in Del(5q) Myelodysplastic Syndromes
- Research Article
- 112
- 10.1093/annonc/mdu180
- Sep 1, 2014
- Annals of Oncology
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Abstract
- 1
- 10.1182/blood.v118.21.2774.2774
- Nov 18, 2011
- Blood
Azacitidine Treatment of Lenalidomide-Resistant Myelodysplastic Syndrome with Deletion 5q
- Abstract
- 3
- 10.1182/blood.v112.11.2682.2682
- Nov 16, 2008
- Blood
Response to Azacytidine (AZA) in MDS or AML with Del 5q : Current Results of the French ATU Program
- Abstract
- 10.1182/blood.v112.11.852.852
- Nov 16, 2008
- Blood
Generation of a Factor Dependent Myeloid Cell Line from Nucleophosmin-1 Heterozygous (NPM-1+/−) Mouse Bone Marrow as a Model for 5q- MDS
- Abstract
- 6
- 10.1182/blood.v116.21.4000.4000
- Nov 19, 2010
- Blood
A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities – Interim Results of the “AZALE” Trial
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.
What is the difference between bacteria and viruses?
What is the function of the immune system?Can diabetes be passed down from one generation to the next?